AbbVie Other Stockholder Equity vs Accounts Payable Analysis

ABBV Stock

USD 169.42 0.85 0.50%

AbbVie financial indicator trend analysis is way more than just evaluating AbbVie Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AbbVie Inc is a good investment. Please check the relationship between AbbVie Other Stockholder Equity and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Other Stockholder Equity vs Accounts Payable

Other Stockholder Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AbbVie Inc Other Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have weak relationship.

The correlation between AbbVie's Other Stockholder Equity and Accounts Payable is 0.3. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of AbbVie Inc, assuming nothing else is changed. The correlation between historical values of AbbVie's Other Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of AbbVie Inc are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Stockholder Equity i.e., AbbVie's Other Stockholder Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Other Stockholder Equity

Accounts Payable

An accounting item on the balance sheet that represents AbbVie obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of AbbVie Inc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from AbbVie's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Sales General And Administrative To Revenue is likely to climb to 0.28 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.8 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	38.8B	40.6B	45.5B	25.2B
Total Revenue	56.2B	58.1B	54.3B	33.8B

Gross Profit Total Revenue

AbbVie fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Property Plant Equipment	Long Term Debt
Common Stock Shares Outstanding		0.6	0.81	0.78	0.73	0.71	0.71	0.53	0.8	-0.29	0.67	0.81	-0.31	0.74	0.66	-0.37	0.44	0.69	0.65	0.74	0.5	0.89	0.07	0.66	0.7	0.36
Total Assets	0.6		0.76	0.85	0.35	0.9	0.97	0.96	0.81	0.31	0.98	0.84	0.29	0.93	0.99	-0.4	0.97	0.95	0.66	0.36	0.99	0.75	0.66	0.97	0.95	0.94
Other Current Liab	0.81	0.76		0.97	0.31	0.94	0.8	0.67	0.97	0.19	0.74	0.96	0.17	0.83	0.78	-0.4	0.7	0.83	0.58	0.36	0.74	0.95	0.51	0.71	0.8	0.66
Total Current Liabilities	0.78	0.85	0.97		0.3	0.97	0.88	0.79	0.97	0.22	0.84	0.96	0.2	0.87	0.86	-0.44	0.8	0.87	0.62	0.34	0.84	0.93	0.55	0.81	0.87	0.76
Total Stockholder Equity	0.73	0.35	0.31	0.3		0.26	0.48	0.29	0.26	-0.52	0.46	0.42	-0.55	0.46	0.4	-0.26	0.14	0.4	0.61	0.98	0.19	0.47	-0.24	0.48	0.47	0.07
Other Liab	0.71	0.9	0.94	0.97	0.26		0.87	0.84	0.96	0.29	0.87	0.93	0.27	0.86	0.9	-0.4	0.87	0.88	0.66	0.28	0.89	0.88	0.62	0.85	0.86	0.84
Property Plant And Equipment Net	0.71	0.97	0.8	0.88	0.48	0.87		0.92	0.81	0.15	0.98	0.89	0.13	0.96	0.98	-0.44	0.89	0.96	0.68	0.52	0.93	0.81	0.53	0.96	0.99	0.84
Net Debt	0.53	0.96	0.67	0.79	0.29	0.84	0.92		0.74	0.19	0.97	0.77	0.17	0.84	0.96	-0.28	0.95	0.87	0.57	0.31	0.95	0.64	0.52	0.98	0.89	0.93
Accounts Payable	0.8	0.81	0.97	0.97	0.26	0.96	0.81	0.74		0.22	0.79	0.93	0.2	0.85	0.83	-0.43	0.76	0.86	0.58	0.3	0.8	0.94	0.54	0.76	0.81	0.73
Cash	-0.29	0.31	0.19	0.22	-0.52	0.29	0.15	0.19	0.22		0.13	0.17	1.0	0.17	0.19	-0.28	0.46	0.22	-0.05	-0.51	0.42	0.1	0.91	0.1	0.16	0.53
Non Current Assets Total	0.67	0.98	0.74	0.84	0.46	0.87	0.98	0.97	0.79	0.13		0.84	0.11	0.92	0.99	-0.36	0.93	0.94	0.69	0.47	0.95	0.75	0.5	1.0	0.96	0.88
Other Assets	0.81	0.84	0.96	0.96	0.42	0.93	0.89	0.77	0.93	0.17	0.84		0.15	0.88	0.85	-0.46	0.77	0.88	0.59	0.48	0.81	0.92	0.51	0.82	0.88	0.74
Cash And Short Term Investments	-0.31	0.29	0.17	0.2	-0.55	0.27	0.13	0.17	0.2	1.0	0.11	0.15		0.15	0.17	-0.22	0.45	0.2	-0.07	-0.54	0.4	0.08	0.9	0.08	0.13	0.51
Net Receivables	0.74	0.93	0.83	0.87	0.46	0.86	0.96	0.84	0.85	0.17	0.92	0.88	0.15		0.95	-0.39	0.85	0.98	0.66	0.48	0.89	0.87	0.56	0.9	0.97	0.78
Good Will	0.66	0.99	0.78	0.86	0.4	0.9	0.98	0.96	0.83	0.19	0.99	0.85	0.17	0.95		-0.38	0.94	0.97	0.68	0.42	0.97	0.78	0.57	0.98	0.97	0.89
Short Term Investments	-0.37	-0.4	-0.4	-0.44	-0.26	-0.4	-0.44	-0.28	-0.43	-0.28	-0.36	-0.46	-0.22	-0.39	-0.38		-0.35	-0.42	-0.29	-0.29	-0.37	-0.41	-0.36	-0.35	-0.43	-0.33
Non Current Liabilities Total	0.44	0.97	0.7	0.8	0.14	0.87	0.89	0.95	0.76	0.46	0.93	0.77	0.45	0.85	0.94	-0.35		0.89	0.55	0.16	0.99	0.65	0.75	0.92	0.87	0.99
Inventory	0.69	0.95	0.83	0.87	0.4	0.88	0.96	0.87	0.86	0.22	0.94	0.88	0.2	0.98	0.97	-0.42	0.89		0.64	0.44	0.93	0.82	0.59	0.91	0.98	0.83
Other Current Assets	0.65	0.66	0.58	0.62	0.61	0.66	0.68	0.57	0.58	-0.05	0.69	0.59	-0.07	0.66	0.68	-0.29	0.55	0.64		0.57	0.59	0.65	0.29	0.68	0.69	0.46
Other Stockholder Equity	0.74	0.36	0.36	0.34	0.98	0.28	0.52	0.31	0.3	-0.51	0.47	0.48	-0.54	0.48	0.42	-0.29	0.16	0.44	0.57		0.21	0.49	-0.22	0.49	0.52	0.08
Total Liab	0.5	0.99	0.74	0.84	0.19	0.89	0.93	0.95	0.8	0.42	0.95	0.81	0.4	0.89	0.97	-0.37	0.99	0.93	0.59	0.21		0.7	0.73	0.93	0.92	0.97
Property Plant And Equipment Gross	0.89	0.75	0.95	0.93	0.47	0.88	0.81	0.64	0.94	0.1	0.75	0.92	0.08	0.87	0.78	-0.41	0.65	0.82	0.65	0.49	0.7		0.45	0.72	0.81	0.59
Total Current Assets	0.07	0.66	0.51	0.55	-0.24	0.62	0.53	0.52	0.54	0.91	0.5	0.51	0.9	0.56	0.57	-0.36	0.75	0.59	0.29	-0.22	0.73	0.45		0.47	0.54	0.77
Intangible Assets	0.66	0.97	0.71	0.81	0.48	0.85	0.96	0.98	0.76	0.1	1.0	0.82	0.08	0.9	0.98	-0.35	0.92	0.91	0.68	0.49	0.93	0.72	0.47		0.94	0.88
Property Plant Equipment	0.7	0.95	0.8	0.87	0.47	0.86	0.99	0.89	0.81	0.16	0.96	0.88	0.13	0.97	0.97	-0.43	0.87	0.98	0.69	0.52	0.92	0.81	0.54	0.94		0.82
Long Term Debt	0.36	0.94	0.66	0.76	0.07	0.84	0.84	0.93	0.73	0.53	0.88	0.74	0.51	0.78	0.89	-0.33	0.99	0.83	0.46	0.08	0.97	0.59	0.77	0.88	0.82

Click cells to compare fundamentals

AbbVie Account Relationship Matchups

AbbVie fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	1.5B	1.7B	1.8B	1.8B	1.8B	1.8B
Total Assets	89.1B	150.6B	146.5B	138.8B	134.7B	81.2B
Other Current Liab	10.4B	17.9B	19.8B	22.5B	30.7B	32.2B
Total Current Liabilities	15.6B	28.7B	35.2B	29.5B	37.8B	39.7B
Total Stockholder Equity	(8.2B)	13.1B	15.4B	17.3B	10.4B	7.1B
Other Liab	18.5B	30.4B	31.0B	31.7B	36.5B	38.3B
Property Plant And Equipment Net	3.0B	5.2B	5.1B	4.9B	5.0B	3.6B
Net Debt	26.8B	77.6B	66.9B	54.1B	46.6B	32.2B
Accounts Payable	1.5B	2.3B	2.9B	2.9B	3.7B	3.9B
Cash	39.9B	8.4B	9.7B	9.2B	12.8B	10.5B
Non Current Assets Total	39.6B	126.4B	118.6B	110.3B	101.7B	57.7B
Other Assets	1.9B	5.1B	4.1B	4.8B	5.6B	5.8B
Cash And Short Term Investments	39.9B	8.5B	9.8B	9.2B	12.8B	11.0B
Net Receivables	5.4B	8.8B	10.0B	11.3B	11.2B	6.8B
Good Will	15.6B	33.1B	32.4B	32.2B	32.3B	18.6B
Short Term Investments	0.0	30M	84M	28M	2M	1.9M
Liabilities And Stockholders Equity	89.1B	150.6B	146.5B	138.8B	134.7B	81.2B
Non Current Liabilities Total	81.7B	108.8B	95.9B	92.0B	86.5B	55.5B
Inventory	1.8B	3.3B	3.1B	3.6B	4.1B	2.2B
Other Stockholder Equity	(9.3B)	15.1B	15.2B	14.7B	13.6B	7.1B
Total Liab	97.3B	137.5B	131.1B	121.5B	124.3B	74.1B
Property Plant And Equipment Gross	3.0B	5.2B	10.7B	11.0B	11.6B	12.2B
Total Current Assets	49.5B	24.2B	27.9B	28.5B	33.0B	23.5B
Accumulated Other Comprehensive Income	(3.6B)	(3.1B)	(2.9B)	(2.2B)	(2.3B)	(2.4B)
Intangible Assets	18.6B	82.9B	76.0B	67.4B	55.6B	32.2B
Property Plant Equipment	3.0B	5.2B	5.1B	4.9B	5.7B	3.4B
Long Term Debt	63.0B	77.6B	64.2B	59.1B	52.2B	41.2B
Short Long Term Debt Total	66.7B	86.1B	76.7B	63.3B	59.4B	49.8B
Non Currrent Assets Other	1.2B	1.2B	1.9B	3.4B	6.6B	6.9B
Short Term Debt	3.8B	8.5B	12.5B	4.1B	7.2B	5.2B
Net Tangible Assets	(42.4B)	(102.9B)	(96.2B)	(82.3B)	(74.1B)	(77.8B)
Retained Earnings	4.7B	1.1B	3.1B	4.8B	(1B)	(950M)
Retained Earnings Total Equity	4.7B	1.1B	3.1B	4.8B	5.5B	3.4B
Long Term Debt Total	63.0B	77.6B	64.2B	59.1B	68.0B	50.1B
Capital Surpluse	15.2B	17.4B	18.3B	19.2B	22.1B	15.8B
Additional Paid In Capital	15.2B	17.4B	18.3B	19.2B	20.2B	15.0B

Pair Trading with AbbVie

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.

Moving together with AbbVie Stock

0.63	ELEV	Elevation Oncology	Pair Corr
0.76	ENVB	Enveric Biosciences	Pair Corr

Moving against AbbVie Stock

0.76	AZN	AstraZeneca PLC ADR	Pair Corr
0.63	PTN	Palatin Technologies Fiscal Year End 26th of September 2024	Pair Corr
0.48	VALN	Valneva SE ADR	Pair Corr
0.48	SLS	Sellas Life Sciences	Pair Corr
0.45	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr

The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.

The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC